Dilution of Verapamil During Intraarterial Administration

Summary

This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary angiography. Patients who are 18 years or older and undergoing non-emergent percutaneous coronary angiography via TRA will be included. Patients who are non-English speaking, pregnant, or intubated will be excluded. Patients will be randomized to one of the two following groups: 1. Group 1 will receive IA Verapamil 5 mg (2mL) diluted with 8 mL of normal saline 2. Group 2 will receive IA Nicardipine 400 mcg (undiluted, 8 mL) The investigators will document the patient's level of discomfort on the Visual Analogue Scale 30 seconds before and after administration of IA Verapamil/Nicardipine. The investigators will also document the presence of radial artery spasms.

Timeline

Start

2022-12-13

Primary completion

2023-12-01

Completion

2023-12-01

Publications

• Patel K, Duckett M, Vidovich MI, Ibrahim K. Intra-arterial nicardipine versus verapamil during transradial access coronary catheterization. Cardiovasc Revasc Med. 2025 May;74:40-44. doi: 10.1016/j.carrev.2024.08.008. Epub 2024 Aug 20.

Drugs

Indications